Literature DB >> 24078181

Mechanism-based selection of a potent kallikrein-related peptidase 7 inhibitor from a versatile library based on the sunflower trypsin inhibitor SFTI-1.

Simon J de Veer1, Svetlana S Ukolova, Christopher A Munro, Joakim E Swedberg, Ashley M Buckle, Jonathan M Harris.   

Abstract

Potent and specific enzyme inhibition is a key goal in the development of therapeutic inhibitors targeting proteolytic activity. The backbone-cyclized peptide, Sunflower Trypsin Inhibitor (SFTI-1) affords a scaffold that can be engineered to achieve both these aims. SFTI-1's mechanism of inhibition is unusual in that it shows fast-on/slow-off kinetics driven by cleavage and religation of a scissile bond. This phenomenon was used to select a nanomolar inhibitor of kallikrein-related peptidase 7 (KLK7) from a versatile library of SFTI variants with diversity tailored to exploit distinctive surfaces present in the active site of serine proteases. Inhibitor selection was achieved through the use of size exclusion chromatography to separate protease/inhibitor complexes from unbound inhibitors followed by inhibitor identification according to molecular mass ascertained by mass spectrometry. This approach identified a single dominant inhibitor species with molecular weight of 1562.4 Da, which is consistent with the SFTI variant SFTI-WCTF. Once synthesized individually this inhibitor showed an IC50 of 173.9 ± 7.6 nM against chromogenic substrates and could block protein proteolysis. Molecular modeling analysis suggested that selection of SFTI-WCTF was driven by specific aromatic interactions and stabilized by an enhanced internal hydrogen bonding network. This approach provides a robust and rapid route to inhibitor selection and design.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  inhibitor library; protease; sunflower trypsin inhibitor

Mesh:

Substances:

Year:  2013        PMID: 24078181     DOI: 10.1002/bip.22231

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  8 in total

1.  Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor.

Authors:  Peng Xu; Mingming Xu; Longguang Jiang; Qinglan Yang; Zhipu Luo; Zbigniew Dauter; Mingdong Huang; Peter A Andreasen
Journal:  J Med Chem       Date:  2015-11-12       Impact factor: 7.446

Review 2.  Remodelling of the tumour microenvironment by the kallikrein-related peptidases.

Authors:  Srilakshmi Srinivasan; Thomas Kryza; Jyotsna Batra; Judith Clements
Journal:  Nat Rev Cancer       Date:  2022-01-31       Impact factor: 69.800

3.  KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.

Authors:  Laetitia Furio; Georgios Pampalakis; Iacovos P Michael; Andras Nagy; Georgia Sotiropoulou; Alain Hovnanian
Journal:  PLoS Genet       Date:  2015-09-21       Impact factor: 5.917

4.  Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.

Authors:  Wenjie Chen; Veronica A Kinsler; Derek Macmillan; Wei-Li Di
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

5.  Mass spectrometry-based determination of Kallikrein-related peptidase 7 (KLK7) cleavage preferences and subsite dependency.

Authors:  Lakmali Munasinghage Silva; Thomas Stoll; Thomas Kryza; Carson Ryan Stephens; Marcus Lachlan Hastie; Helen Frances Irving-Rodgers; Ying Dong; Jeffrey John Gorman; Judith Ann Clements
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

6.  Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.

Authors:  Jun Tian; Vivian Wang; Ni Wang; Baharak Khadang; Julien Boudreault; Khldoun Bakdounes; Suhad Ali; Jean-Jacques Lebrun
Journal:  Breast Cancer Res       Date:  2021-02-15       Impact factor: 6.466

7.  Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.

Authors:  Laetitia Furio; Simon de Veer; Madeleine Jaillet; Anais Briot; Aurelie Robin; Celine Deraison; Alain Hovnanian
Journal:  J Exp Med       Date:  2014-02-17       Impact factor: 14.307

8.  Potent, multi-target serine protease inhibition achieved by a simplified β-sheet motif.

Authors:  Xingchen Chen; Blake T Riley; Simon J de Veer; David E Hoke; Jessica Van Haeften; Darren Leahy; Joakim E Swedberg; Maria Brattsand; Perry J Hartfield; Ashley M Buckle; Jonathan M Harris
Journal:  PLoS One       Date:  2019-01-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.